Company Number: 13297197

Analysis Date: 2025-07-20 13:48 UTC

1. Risk Rating: LOW
   JNJMedcare Ltd demonstrates a solid net asset position, strong working capital, and no overdue filings, which collectively suggest low immediate risk in terms of solvency and regulatory compliance.

2. Key Concerns:

• Relatively Small Scale of Operations: Classified as a micro-entity with only 2 employees on average, which could limit operational scalability and resilience.
• Director Related Creditors: The company owes a small but non-trivial amount (£2,783) to directors, which requires monitoring for potential related-party transaction risks.
• Limited Financial Disclosure: Only balance sheet and limited financial data filed (micro-entity exemption), no income statement available publicly, restricting a full assessment of profitability and cash flow.

3. Positive Indicators:

• Strong Net Current Assets: Substantial increase in net current assets from £32,684 in 2023 to £87,192 in 2024, indicating improved liquidity.
• Solvent Balance Sheet: Shareholders’ funds have grown significantly to £93,189 as of March 2024, showing increasing equity and asset coverage of liabilities.
• Compliance with Filings: All statutory accounts and confirmation statements are filed on time, with no overdue returns or penalties noted.
• Stable Director and PSC Structure: Directors and persons with significant control appear stable with clear ownership and control rights.

4. Due Diligence Notes:

• Profitability and Cash Flow: Obtain or review internal management accounts or bank statements to verify ongoing operational cash flows and profit generation, as only balance sheet data is available.
• Related Party Transactions: Review details and terms of amounts owed to directors to ensure no undue financial risk or governance issues.
• Business Model and Market Position: Understand the company’s client base, revenue sources, and growth prospects in the specialist medical practice sector (SIC 86220).
• Director Changes: Investigate reasons for the two director resignations in July 2024 to assess any governance or operational impact.
• Audit or Review Status: Consider requesting an audited or reviewed set of accounts in future to enhance transparency and risk assessment.